Zydus Lifesciences to launch protection against new strain of influenza virus

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives

Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives

Bionova Scientific aims to set up new Plasmid DNA GMP facility neat Houston, US

Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

G20 New Delhi Leaders' Declaration on strengthening global health

The Leaders of G20 met in New Delhi and committed to strengthening global health and implementing one health approach

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

Agilent announces LC/TQ and LC/Q-TOF mass spectrometry solutions

The superior Agilent 6495 Triple Quadrupole LC/MS (LC/TQ) System is ideal for demanding and challenging targeted analysis applications requiring the highest analytical sensitivity